Essential medicines for pediatric oncology in developing countries

@article{Mehta2013EssentialMF,
  title={Essential medicines for pediatric oncology in developing countries},
  author={P S Mehta and John T. Wiernikowski and Jennifer A. Petrilli and Ronald D. Barr},
  journal={Pediatric Blood \& Cancer},
  year={2013},
  volume={60}
}
The burden of cancer in children in low and middle income countries (LMICs) is substantial, comprising at least 80% of incident cases globally, and an even higher proportion of cancer‐related deaths. With survival rates exceeding 80% in high income countries, it is imperative to transfer these successes to LMICs. A major challenge is the poor availability of safe, cost‐effective chemotherapy. A list of 51 drugs—chemotherapeutics, infectious disease agents, and supportive care medications—is… 
View on Wiley
isites.harvard.edu
33 Citations
Highly Influential Citations
1
Background Citations
11

33 Citations

Citation Type

Citation Type

Challenges in managing infections among pediatric cancer patients: Suboptimal national essential medicines lists for low and middle income countries
TLDR
The selection of antimicrobial agents for national essential medicines lists in LMICs warrants attention from a pediatric cancer perspective and frequency and corresponding 95% confidence limits are assessed.
Proposing Essential Medicines to Treat Cancer: Methodologies, Processes, and Outcomes.
  • L. Shulman, C. Wagner, +6 authors N. Magrini
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2016
TLDR
The list of medications proposed, and the ability to link each recommended medicine to specific diseases, should allow public officials to apply resources most effectively in developing and supporting nascent or growing cancer treatment programs.
Use of Fungal Diagnostics and Therapy in Pediatric Cancer Patients in Resource-Limited Settings
TLDR
This review presents relevant, up-to-date information about the most common opportunistic and endemic fungal diseases among children with cancer, their geographic distribution, and recommended diagnostics and treatment.
Childhood cancer in Africa
TLDR
The purpose of the paper is to describe the current status of childhood cancer treatment in Africa, as documented in publications, dedicated websites and information collected through surveys.
Global Approach to Hematologic Malignancies.
Improving Care for Children With Cancer in Low‐ and Middle‐Income Countries—A SIOP PODC Initiative
TLDR
The development of adapted guidelines, advocacy and awareness, education and training, and global mapping have been the initial areas of focus, and the impact of some of these activities is evident, for example, in the SIOP Africa PODC Collaborative Wilms tumor project.
Shortages and price variability of essential cytotoxic medicines for treating children with cancers
TLDR
Problems with the availability of essential medicines, dependable supply chains, confidential medicine prices and wide variability in treatment costs contribute to persistent challenges in the care of children with treatable cancers, especially in LMICs.
Toward the Cure of All Children With Cancer Through Collaborative Efforts: Pediatric Oncology As a Global Challenge.
TLDR
Childhood cancer burden has been shifted toward low- and middle-income countries and, for that reason, global initiatives directed at pediatric cancer care and control are needed.
The role of SIOP as a platform for communication in the global response to childhood cancer
TLDR
Current worldwide interventions to improve childhood cancer from the perspective of the International Society of Paediatric Oncology (SIOP) are described to strengthen the communication among and synergistic effects of various paediatric cancer stakeholders.
Chemotherapy induced thrombocytopenia in pediatric oncology.
...
1
2
3
4
...

References

SHOWING 1-10 OF 33 REFERENCES
A formulary for pediatric oncology in developing countries
TLDR
The focus on pediatric oncology, that was embedded in the 1994 proposal, was omitted from the later recommendation from WHO, and antineoplastics, immunosuppressives, and medicines used in palliative care are among the sections of theModel List recommended for review with high priority.
Global child health priorities: what role for paediatric oncologists?
Treatment strategies and regimens of graduated intensity for childhood acute lymphoblastic leukemia in low‐income countries: A proposal
TLDR
This proposal provides a framework that LIC centers can use to provide effective ALL therapy, particularly in regions of the world where few children are currently being cured.
Essential drugs for cancer therapy: a World Health Organization consultation.
  • K. Sikora, S. Advani, +6 authors S. Yan
  • Medicine, Political Science
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 1999
TLDR
Adequate supportive care programmes with the widespread availability of effective drugs for pain control are of considerably greater importance and drugs in the third group are judged as currently not essential for the effective delivery of cancer care.
Chemotherapy drug shortages in the United States: genesis and potential solutions.
TLDR
In October 2011, the US Food and Drug Administration announced the end of the cytarabine shortage, but in July 2011, shortages of daunorubicin started, another drug critical to the management of leukemia and the second most important drug used to treat acute myeloid leukemia.
The oncology pharmacy in cancer care delivery in a resource-constrained setting in western Kenya
  • R. Strother, Kamakshi V. Rao, +6 authors P. Loehrer
  • Medicine
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
  • 2012
TLDR
The experience and lessons learned in establishing a chemotherapy pharmacy in western Kenya are described, which help to both mitigate the risks to practitioners and patients, and also limit the costs of cancer care and the environmental impact of chemotherapeutics.
Imatinib mesylate in children and adolescents with cancer
  • R. Barr
  • Biology, Medicine
    Pediatric blood & cancer
  • 2010
TLDR
The drug is now included as front‐line therapy for CML and Philadelphia chromosome‐positive acute lymphoblastic leukemia in children and adolescents, though valid concerns about serious late sequelae remain unresolved and are important issues for further study.
A survey of resources and activities in the MISPHO family of institutions in Latin America: A comparison of two eras
In developing countries, implementation of effective pediatric cancer programs can reduce the overall rate of childhood mortality. To promote this objective, Monzas International School of Pediatric…
Closing the Cancer Divide: A Blueprint to Expand Access in Low and Middle Income Countries
TLDR
Meet the challenge of cancer in LMICs is unnecessary, unaffordable, unattainable, and – perhaps the most pernicious – inappropriate because such an effort would take away resources from other high burden, communicable diseases.
Outcome of acute promyelocytic leukemia (APL) in children and adolescents: an analysis in two consecutive trials of the European APL Group.
  • C. Bally, J. Fadlallah, +16 authors L. Adès
  • Medicine, Psychology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2012
TLDR
Adolescents and children age > 4 years with APL treated with ATRA and chemotherapy have outcomes at least as favorable as those of adults, and younger children seem to experience more relapses and may require reinforcement of first-line treatment.
...
1
2
3
4
...